Paolo Morgese of Merck Serono and Peter Wagner and Maximilian Schwarz of Mederi present 5 tips for matching stakeholders’ value expectations with demonstration of value
Nathalie Horowicz-Mehler and John J Doyle explain why comparative effectiveness research (CER) must include patients’ perspectives on how to balance risk and benefit
Medical scientific liaisons (MSLs)—the people physicians talk to when they have scientific questions—have traditionally been separated from the marketing and commercial functions. Should the boundaries between the two functions be broken down?
The proliferation of stakeholders makes oncology market access increasingly complexand successful models increasingly essential. Peter Mansell reports.